New study monitors Darolutamide's safety in korean prostate cancer patients
NCT ID NCT06334120
First seen Nov 01, 2025 · Last updated May 14, 2026 · Updated 24 times
Summary
This observational study follows 600 Korean men with prostate cancer who are already prescribed darolutamide. The goal is to track side effects and see how well the drug works over one year. Researchers will review medical records during routine doctor visits every 2 to 4 months.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METASTATIC HORMONE-SENSITIVE PROSTATE CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Multiple locations
RECRUITINGMultiple Locations, South Korea
Conditions
Explore the condition pages connected to this study.